Ppm11 Tumour-Specific Randomized Controlled Trials in Rare Oncogene-Driven Cancers: Asking for the Impossible?

Lozano‐Ortega, Greta; Hodgson, Matt; Csintalan, F.; Zerbini, C.; Johnston, Karissa; Nam, Julian

doi:10.1016/j.jval.2019.09.2328

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Отсутствие контрольной группы. В связи с редкостью и гетерогенностью изучаемой популяции невозможно набрать проспективно контрольную группу пациентов [4]. Для того чтобы сравнить эффективность TRK-ингибиторов со стандартной терапией, могут использоваться другие способы, такие как сравнение эффективности с предшествующей линией терапии [5] или ретроспективное сравнение с когортой сопоставимых по клиническим характеристикам пациентов из доступных регистров [6].…”

Section: Consensusunclassified

Resolution of the advisory board on the topic: “The place of entrectinib in the treatment of adult patients with NTRK-fusion positive solid tumors”

Breder,

Zhukova,

Bolotina

et al. 2023

J. Mod. Onco.

View full text Add to dashboard Cite

show abstract

Section: Consensusunclassified

Resolution of the advisory board on the topic: “The place of entrectinib in the treatment of adult patients with NTRK-fusion positive solid tumors”

Breder,

Zhukova,

Bolotina

et al. 2023

J. Mod. Onco.

View full text Add to dashboard Cite

show abstract

“…«Золотым стандартом» доказательности в медицине являются рандомизированные клинические исследования (РКИ), однако для редких типов опухолей проведение РКИ может быть недоступно [21]. На примере перестроек NTRK показано, что до получения результатов РКИ, изучающего папиллярный РЩЖ (ПРЩЖ), должно пройти 87 лет, для АРЩЖ -104 года [22]. Однако уже сейчас есть категория пациентов, которые нуждаются в этом лечении по жизненным показаниям, поэтому невозможно ждать результаты так долго.…”

Section: корзинные исследованияunclassified

Personalized approach in the treatment of thyroid cancer: A review

Раджабова¹

2022

Consilium Medicum

View full text Add to dashboard Cite

The main goal is to improve treatment outcomes of disseminated inoperable thyroid cancer through a personalized choice of targeted agents. Considering gene mutations in drug choice will further improve the survival of patients with rare mutations. Despite the small sample of patients, mutation detection, regardless of localization, and basket studies will allow future results to be obtained much faster than in a dozen years and use these results in this rare category of patients. Basket studies allow patients with rare disorders to receive personalized therapy according to mutations in tumor tissue, regardless of the affected organ.

show abstract

Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors

et al. 2023

View full text Add to dashboard Cite

Background Clinical trials have reported the efficacy of tropomyosin receptor kinase (TRK) inhibitors against neurotrophic receptor tyrosine kinase (NTRK) fusion gene-positive advanced solid tumors. The accumulated evidence of tumor-agnostic agent has made since TRK inhibitors were approved and used in clinical practice. Therefore, we have revised the ‘Japan Society of Clinical Oncology (JSCO)/Japanese Society of Medical Oncology (JSMO)-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors, cooperated by the Japanese Society of Pediatric Hematology/Oncology (JSPHO)’. Methods Clinical questions regarding medical care were formulated for patients with NTRK fusion-positive advanced solid tumors. Relevant publications were searched by PubMed and Cochrane Database. Critical publications and conference reports were added manually. Systematic reviews were performed for each clinical question for the purpose of developing clinical recommendations. The committee members identified by JSCO, JSMO, and JSPHO voted to determine the level of each recommendation considering the strength of evidence, expected risks and benefits to patients, and other related factors. Thereafter, a peer review by experts nominated from JSCO, JSMO, and JSPHO, and the public comments among all societies' members was done. Results The current guideline describes 3 clinical questions and 14 recommendations for whom, when, and how NTRK fusion should be tested, and what is recommended for patients with NTRK fusion-positive advanced solid tumors. Conclusion The committee proposed 14 recommendations for performing NTRK testing properly to select patients who are likely to benefit from TRK inhibitors.

show abstract

Ppm11 Tumour-Specific Randomized Controlled Trials in Rare Oncogene-Driven Cancers: Asking for the Impossible?

Cited by 3 publications

References 0 publications

Resolution of the advisory board on the topic: “The place of entrectinib in the treatment of adult patients with NTRK-fusion positive solid tumors”

Resolution of the advisory board on the topic: “The place of entrectinib in the treatment of adult patients with NTRK-fusion positive solid tumors”

Personalized approach in the treatment of thyroid cancer: A review

Contact Info

Product

Resources

About